Issues & Advocacy

SNMMI's mission with regard to health policy and regulatory affairs is to enhance its credibility, advance its issues, and through leadership become a valued partner among public policy stakeholders.


  • July 19, 2018SNMMI Supports Bill Funding Mo-99 Domestic Production
    In a letter to the Senate and House subcommittees on Energy and Water Development, SNMMI President Satoshi Minoshima, MD, PhD, joined with leaders of other medical societies, patient groups, radiopharmaceutical manufacturers and distributors, and medical imaging companies to urge support of a provision in both the Senate and House bills that would provide $20 million in additional funding to continue establishing domestic production of Mo-99.
  • July 13, 2018CMS Proposes 2019 Payment Rule for Physicians
    CMS issued its CY 2019 proposed payment policies and payment rates for services furnished under the Medicare Physician Fee Schedule.
  • July 12, 2018Availability of Mo-99
    Nuclear reactors in both South Africa and Australia are off-line for unscheduled reasons. Efforts are being made to reduce the impact on patients.
  • July 10, 2018SNMMI-ACNM-ASTRO Submit Joint Comments to NRC on Training and Experience Requirements
    SNMMI together with representatives from ACNM and ASTRO offered recommendations for potential updates to the Nuclear Regulatory Commission’s requirements for those who wish to be authorized users of unsealed byproduct material.
  • July 3, 2018SNMMI Opposes Florida Proposal
    SNMMI responds to an attempt to withdraw Medicare coverage of DAT-SPECT with Iodine I-123 Ioflupane (DatScan).
  • June 12, 2018The AMA's RUC and Why It Is Important to You
    The American Medical Association (AMA) has an expert panel called the Relative Value Scale Update Committee (RUC), which advocates for accurate valuation of all physician services. If you receive a request from SNMMI to participate in an AMA RUC survey, it is imperative that you participate so your voice can be heard.
  • May 29, 2018Comments Sent to FDA Regarding Amino Acids Needed During Lu-177 DOTATATE Therapy
    SNMMI, the Mayo Clinic, Washington University School of Medicine in St. Louis, and Memorial Sloan Kettering Cancer Center have jointly filed comments with the FDA with recommendations for regulatory changes that would make it easier for patients with GEP-NETs to obtain arginine and lysine--amino acids that can mitigate side effects of Lu-177 DOTATATE therapy.
  • May 21, 2018SNMMI Advocates for Improved Reimbursement at CMS Public Meeting
    SNMMI recently advocated on behalf of members and their patients at the Centers for Medicare and Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) workgroup public meeting. Lu-177-dotatate, Ga-68-dotatate, and Fl-18-fluciclovine are all delivered by pharmacies in per-study doses, not per-unit doses; SNMMI requested that CMS modify the coding descriptors for payment accordingly.

  • Click For More Government Relations News